Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
23 February 2025 | Story André Damons | Photo Supplied
UFS Main Building
The University of the Free State in partnership with the Department of Science, Technology and Innovation (DSTI), will form the backdrop for the G20 Research and Innovation Working Group (RIWG) and G20 Initiative on Biochemistry (GIB) meetings in February.

The University of the Free State (UFS) will form the backdrop for the G20 Research and Innovation Working Group (RIWG) and G20 Initiative on Bioeconomy (GIB) meetings on 23 and 24 February 2024.

UFS has, over the years, distinguished itself as a leader in the research and development, particularly in the biodiversity space through its African Medicines, Innovations and Technologies Development (AMITD) platform, which was established in collaboration with the Department of Science, Technology and Innovation (DSTI) and its entity, the Technology Innovation Agency.  It was therefore an obvious choice for the institution to again partner with the DSTI to host the G20 meetings.

The G20 is an international forum comprising many of the world's largest developing and developed economies, established to tackle pressing global economic and financial issues.

South Africa holds the G20 Presidency this year – only five years before the UN's 2030 Agenda for Sustainable Development deadline.  This is the first time the G20 is being hosted on African soil.

South Africa's presidency takes place when the world is facing a series of overlapping and mutually reinforcing crises, including climate change, underdevelopment, inequality, poverty, hunger, unemployment, technological changes, and geopolitical instability.

The G20 RIWG provides a platform for addressing global challenges through research, technology and innovation.  The DSTI will lead the RIWG under the leadership of Minister Blade Nzimande and explore this year's theme, "Equity in science and innovation-based approaches to sustainable development".

Prof Nzimande, along with Prof Hester Klopper, Vice-Chancellor and Principal of UFS, will both deliver opening remarks at the meeting.

The session on 23 February will be the first to include G20 officials engaging with indigenous knowledge holders, students and researchers in the bioeconomy.

Prof Motlalepula Matsabisa, Director of the Department of Pharmacology and AMITD at UFS, says the university was an excellent choice to host the sessions because of its trusted relationships with indigenous communities and focus on inclusive research and development.

The G20 dialogues aim to be inclusive and provide a space for members of the public to voice their aspirations and to capture their needs around the indigenous knowledge and biodiversity in which they play an integral role.

"I am honoured to be part of this global event.  I am so happy that AMITD is now globally recognised.  We will exhibit our research conducted with communities on the internationalisation of South African science research in traditional medicines and biodiversity, and its formal commercialisation," said Prof Matsabisa.

"We are the leader in traditional medicines research and development.

"South Africa always leads in global debates and sets the stage for African views to be heard.  We will contribute to policies on global biodiversity and bioeconomy and commercialisation of our natural resources through equity, sustainability and solidarity.

Prof Matsabisa believes this event will also highlight the goals of the DSTI's 2019 White Paper on Science, Technology and Innovation and the implementation of its 2022-2032 Decadal Plan.

He hopes to see tangible and meaningful outcomes from the G20 discussions that will be implemented by the USA when it takes over the G20 Presidency for 2026.

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept